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NF-κBes neurological disease as well as HIV-1 does. Induction of COX-2 in CNS of HIV-1
infected people has been proposed as a cause of cognitive impairment, so we tested whether HIV-2 may
cause damage by a similar mechanism. COX-2 mRNA and protein expression were induced in human
astrocytes upon interaction with HIV-2, being this induction abrogated by CXCR4 antagonists. HIV-2 induced
COX-2 promoter transcription and deletion of the two NF-κB binding sites of the promoter abrogated this
induction. Neither AP-1 nor NFAT seem to be involved in COX-2 transcriptional activation. Overexpression of
IκBα completely abrogated COX-2 induction, and transfection of p65/relA NF-κB induced COX-2
transcription. Interestingly, HIV-2 activated NF-κB by inducing p65/relA transactivating activity through
Ser536 phosphorylation. Moreover, the astrocyte activation induced by HIV-2 was abrogated by different
COX inhibitors. In summary, HIV-2 induces COX-2 in human astrocytes depending on CXCR4 coreceptor.
© 2008 Elsevier Inc. All rights reserved.IntroductionBoth HIV-1 and HIV-2 belong to the “primate lentivirus” subgenus,
and although they present a similar genomic organization, there are
important differences between them that provide insights into virus
evolution, tropism and pathogenesis. Major differences include
reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune
control of HIV-2 infection and often some degree of CD4-indepen-
dence for HIV-2 infection (Reeves and Doms, 2002). Despite this lower
pathogenicity, HIV encephalitis (HIVE) has been reported as more
frequent in brains of HIV-2 infected patients than HIV-1 (Lucas et al.,
1993). In addition, the reported independency from CD4 (Endres et al.,
1996) to establish a productive infection could account for the higher
neuropathogenicity of HIV-2. Recent studies showed that a subset of
HIV-1 and HIV-2 isolates were able to replicate in primary adult
astrocytes, brain microvascular endothelial cells, and macrophages
using an alternative coreceptor(s) to enter the cell (Clapham and
McKnight, 2002; Willey et al., 2003). However, since no productive
neuronal infection is evident in the brain of HIVE patients, other
indirect mechanisms must be responsible for the neuropathological
damage observed in the brain of HIV-infected people (Reeves and
Doms, 2002).
In this regard, recent ﬁndings support the role of cyclooxygenase-
2 (COX-2) in the neuropathogenicity of HIV-1 (Alvarez et al., 2005;
Flora et al., 2006). COX is the rate-limiting enzyme in the productionM.Á. Muñoz-Fernández).
l rights reserved.of prostaglandins (PGs) from arachidonic acid (AA). Two isoforms
have been identiﬁed, the constitutively expressed COX-1 and COX-2
that is induced by different stimuli (Smith, DeWitt, and Garavito,
2000; Vane, Bakhle, and Botting, 1998). Human COX-2 promoter
contains a classical TATA box and multiple regulatory elements,
including two putative nuclear factor (NF)-κB-binding sites, one NF-
interleukin (IL)6/CCAAT-enhancer binding protein (cEBP), one acti-
vator protein (AP)-1, one cyclic AMP-response element and two
binding sites of NF of activated T-cells (NFAT). These sequences have
been shown to act as positive regulatory elements for the COX gene
transcription in different cell types (Allport et al., 2000; Alvarez et al.,
2005; Alvarez et al., 2007; Iniguez et al., 2000).
NF-κB is a collective term referring to a class of dimeric trans-
cription factors belonging to the rel family. In resting cells, NF-κB
exists in the cytoplasm as an inactive complex bound to inhibitory
proteins of the IκB family. In response to a variety of stimuli, IκB
proteins undergo phosphorylation of Ser32 and Ser36 followed by
ubiquitination and subsequent degradation, allowing translocation of
active NF-κB to the nucleus. However, there is accumulating evidence
suggesting that another level of NF-κB regulation independent on IκB
degradation exists. This second level of regulation relies in the
activation of the transcriptional activity of p65/relA and c-rel NF-κB
members (reviewed in Schmitz, Bacher, and Kracht, 2001; Viatour
et al., 2005). Therefore, phosphorylation (Anrather et al., 1999;
Sizemore, Leung, and Stark, 1999) and acetylation (Deng, Zhu, and
Wu, 2003) of NF-κB represent another important level of regulation.
After strong activation, astrocytes secrete various neurotoxic subs-
tances and express an enhanced level of glial ﬁbrillary acidic protein
(GFAP), which is considered a marker for astrogliosis (Eng and
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expression of GFAP is increased in neurodegenerative CNS remains
unclear.
In this work, we have found that although HIV-2CBL23 does not
infect U-87 cells, it is able to induce COX-2 expression at the trans-
criptional level by activating NF-κB. This activation seems to involve
Ser536 phosphorylation of p65/relA subunit and not IκBα degrada-
tion. Finally, we demonstrate that HIV-2 induces an increase in GFAP
expression in U-87 cells, being this effect reverted by COX-2 inhibitors.
Results
HIV-2 induces COX-2 expression in human astrocytes
Most inﬂammatorymediators have relatively fewactions in healthy
CNS tissue and are expressed at very low or undetectable levels.
However, they are induced rapidly in response to tissue injury or
infection, and exert diverse actions. In this regard, it has been pre-
viously described that HIV-1 induces COX-2 expression in brain cells
(Alvarez et al., 2005; Alvarez et al., 2007). So, we wanted to determine
whether HIV-2 virus similarly induced COX-2 synthesis in astroglial
cells. To test whether HIV-2CBL23 isolate was able to infect human
astrocytes, ﬁrst of all we conﬁrmed the presence of different cellular
receptors on U-87 cells by RT-PCR. As expected, CXCR4-mRNA but not
CD4-mRNA was detected in these cells (Fig. 1A). Those results were
conﬁrmed at the cell surface by ﬂow cytometry (Fig. 1A). To determine
whether HIV-2 virus could infect human astrocytes, we cultured those
cells in the presence of HIV-2CBL23 isolate at different MOI and after 3
days, viral production was measured by ELISA. Although U-87 cells
were unable to produce new virus (Fig. 1B), HIV-2 induced COX-2
mRNA expression analyzed by real-time RT-PCR, in a dose-dependent
manner (Fig. 1C), suggesting that COX-2 induction was mediated
merely by binding of the envelope glycoprotein to CXCR4 and not by
viral infection per se. This result was conﬁrmed by using monoclonal
antibodies against CXCR4 as well as the CXCR4 antagonist, AMD3100
and measuring COX-2mRNA induction by HIV-2. In both cases, we
found a decrease in COX-2mRNA induction (Fig. 1C). Moreover, HIV-
2CBL23was able to induce COX-2 protein expression inU-87 cells aswell
as in human primary astrocytes, analyzed by Western blot. Although
COX-2 protein was already detectable in unstimulated cells (Fig. 1D),
after culture with HIV-2, a heavily increase in protein levels at 6 h was
observed, which subsequently decreased after 24 and 48 h of culture.
Accordingly, we found PGE2 production increased over basal levels
after 16 h of treatment so much at U-87 cells as in primary astrocytes
(Fig. 1E). The selective inhibitor of COX-2, NS-398, totally abrogated
PGE2 production in U-87 cells conﬁrming the main role of COX-2
isoform on PGE2 synthesis.
HIV-2 induces COX-2 promoter activity in U-87 cells
The above results suggested that HIV-2 interaction with glial cells
was able to induce COX-2 at the transcriptional level. To further
address this, we transfected glial cells with the COX-2 promoter
containing a region spanning from −1796 to +104 bp relative to the
transcription start site of the human COX-2 gene in the luciferase
reporter plasmid pXP2 (P2-1900). The transfected cells were cultured
in the presence of HIV-2CBL23 (MOI 1), and 16 h later, luciferase activity
was measured. P2-1900 COX-2 promoter activity was up-regulated
(more than 2 fold) in the presence of HIV-2 (Fig. 2A). To investigate
whether CXCR4 receptor was required for this induction, U-87
transfected cells were pretreated with AMD3100 (50 μM) during
30min at 37 °C, before HIV-2 addition to the cells for 16 h. As shown in
Fig. 2A, the HIV-2-induced COX-2 transcriptional activity was
absolutely abrogated in the presence of AMD3100, indicating again
that HIV-2-dependent COX-2 induction occurred through its interac-
tion with CXCR4 receptor.To gain some insight into the pathways involved in HIV-2CBL23
induction of COX-2 transcription, we ﬁrst determined the region
within the COX-2 promoterwhich responded toHIV-2 byusing a series
of deletion mutants derived from the COX-2 5′upstream regulatory
sequence through transfection assays. The P2-431 plasmid has a dele-
tion of a distal NF-κB site, whereas the P2-274 presents a deletion of
both NF-κB sites in the COX-2 promoter, keeping intact NFAT, AP-1 or
CRE sites (Iniguez et al., 2000). As shown in Fig. 2B, deletion up to −327
(P2-431) strongly abrogated HIV-2 inducibility, and further deletions
up to−170 (P2-274) increased this effect. Those results suggested that 2
regions between −1786 and −327 were necessary for COX-2 induction.
NF-κB is required for COX-2 induction by HIV-2 in human astrocytes
Although the above results indicated that NF-κB activation was
required for HIV-2 induction of COX-2 in U-87 cells, we wanted to
discardwhether HIV-2 induced NFAT, or AP-1 activity.We observed no
increase in the transcriptional activity of reporter genes under control
of AP-1 or NFAT sites in U-87 cells upon culture with HIV-2 (Fig. 3A)
discarding any contribution of any of these factors in COX-2 induction
in glial cells by HIV-2CBL23. In contrast, as shown in Fig. 3A, HIV-2CBL23
caused a marked increase of around 3–4 fold on average of a NF-κB-
dependent luciferase reporter plasmid in HIV-2-U-87 cells compared
to control cells.
To further investigate this activity, U-87 cells were transiently co-
transfected with the active NF-κB member p65/relA or the inhibitory
subunit IκBα and P2-1900 COX-2-luc reporter plasmid. Overexpres-
sion of p65/relA was able, to increase transcriptional activity of COX-2
promoter in those cells (Fig. 3B) (an average of 4.1 fold) over control
cells transfected with the empty vector. Besides, p65/relA over-
expression synergistically cooperated with HIV-2 in inducing COX-2
promoter activity (around 16 fold). Interestingly, transfection of IκBα
completely abrogated HIV-2-induced COX-2 promoter activity. Taken
together the above results suggest that NF-κB is themain transcription
factor induced by HIV-2 involved in COX-2 transcription in U-87 cells.
To check this fact in primary cultures, we pretreatedNHA cellswith the
agent PDTC before contact with HIV-2 and after 16 h of culture, PGE2
productionwasmeasured in the supernatants. As you can see in Fig. 3C,
it is totally clear that NF-κB is really involved in PGE2 production not
only in established cell lines but also in primary astrocytes.
Activation of NF-κB by HIV-2CBL23 is associated with increases in the
transactivation function of p65/relA
The activation of NF-κB usually involves the degradation of IκBα
subunit bound to NF-κB dimer allowing its translocation to the
nucleus where it binds and activates NF-κB-dependent genes. Thus, to
investigate the mechanisms by which HIV-2 induces NF-κB activation,
levels of NF-κB/p65/relA and IκBα were studied by Western blot. As
shown in Fig. 4A, p65/relA was present in nuclear extracts of control
U-87 cells. This fact was not due to cytoplasmic contamination in the
nuclear fraction (data not shown). More surprisingly, upon HIV-2
interaction there was no change neither in cytoplasmic nor in nuclear
levels of p65/relA, as it would be expected if an increase in p65/relA
translocation had taken place. At the same time similar total levels of
IκBα were observed at any time tested after HIV-2 culture, indicating
that IκBα degradation is not taking place upon HIV-2 contact in these
cells.
All data indicated that HIV-2 was inducing the NF-κB activity
without altering p65/relA nuclear translocation or IκBα degradation.
However, the second mechanism to regulate NF-κB activity, without
IκBα degradation, involving Ser536 and/or Ser529 phosphorylation in
the transactivation domain of p65/relA has been described (Schmitz,
Bacher, and Kracht, 2001). This pathway involves the phosphorylation
of p65/relA or c-rel in several sites of their transactivation domains,
leading to an increase in the transactivation activity. To conﬁrm this
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study of transcription factor activities independently of nuclear
translocation. U-87 cells were transfected with a reporter constructin which luciferase expression is driven by four tandem copies of the
responsive element for the yeast transcription factor Gal4 (pGal4-Luc)
along with expression vectors containing fusion of the DNA binding
Fig. 2. Analysis of COX-2 transcriptional activity induced by HIV-2CBL23. (A) HIV-2 induces COX-2 promoter activity. U-87 cells were transfected with COX-2 promoter construct and
cultured in the presence of HIV-2CBL23 (MOI 1) alone or in combinationwith AMD3100. (B) U-87 cells were transfected with the indicated COX-2 promoter constructs and cultured in
the presence of HIV-2CBL23 isolate for 16 h and assayed for luciferase activity. Assays were performed in triplicate and are expressed as fold induction about basal values of untreated
cells. Differences from HIV-2CBL23 induction of full promoter (P2-1900): ⁎p= 0.02; –, non-signiﬁcant.
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relA, either in the wild type version or in a form mutated in Ser529
and Ser536. HIV-2 increased the transactivation a Gal4-luc reporter
mediated by Gal4-p65 in U-87 cells, by around 2 fold on average, but
not by the Ser529 and Ser536 mutant Gal4-p65 form (Fig. 4B). The
above results indicated that phosphorylation of p65/relA at Ser536,
which is a key modiﬁcation that potentiates p65/relA transactivation
function, hence activation (Schmitz, Bacher, and Kracht, 2001;
Sizemore, Leung, and Stark, 1999; Viatour et al., 2005), was involved
in HIV-2 induction of NF-κB. Thus, we tested whether HIV-2 affected
phosphorylation of endogenous p65/relA at Ser536 through Western
blot. As shown in Fig. 4C, culture of U-87 cells in the presence of HIV-
2CBL23 led to a signiﬁcantly level of p65/relA phosphorylation at the
Ser536 position higher than in control cells.
HIV-2 increases GFAP expression
It is well established that GFAP is increased during activation of
astrocytes and astrogliosis. To determine the effect of HIV-2 on GFAP
expression, we cultured U-87 cells in contact with HIV-2CBL23 and after
16 h we examined its expression by immunoﬂuorescence assay. TheFig.1. COX-2 expression is induced in human astrocytes after culturing with HIV-2. (A) Expres
ampliﬁed with CD4, and CXCR4-speciﬁc primers. (A2) Flow cytometry analysis of CD4 and CX
U-87 cells were infected at MOI 1, and Agp24 was quantiﬁed in the supernatants of cultures 3
(C) COX-2 mRNA induction detected by real-time PCR. Cells were cultured with HIV-2CBL23 (M
were collected. RT-PCR ampliﬁcation was performed using 200 ng of total RNA using Ligh
detected by Western blot analysis. (E) PGE2 release in the supernatant of those cells after 16
from HIV-2CBL23-production of PGE2 in human astrocytes: ⁎pb0.01; ⁎⁎p=0.02.results showed a signiﬁcantly higher level of GFAP expression in
stimulated cells compared to control (Fig. 5).
To investigate whether COX-2 induction was involved in this
activation, U-87 cells were cultured with HIV-2CBL2 in the presence of
several COX-2 inhibitors. NS-398 and ibuprofen were able to decrease
GFAP expression in HIV-2-U-87 cells suggesting a role of COX-2
protein in astroglial activation (Fig. 5). We discarded that the decrease
in GFAP expression was due to toxicity of these inhibitors on cell
cultures since any of them did not produce cell death measured by
MTT assay (data not shown).
Discussion
There are very few studies concerning HIV-2 and even less about
its neuropathogenicity, nonetheless the fact is that HIV-2 would
certainly provide a good model for HIV-1 related neurotoxicity.
Although the incidence of HAD has markedly decreased since it has
become possible to effectively control viral replication by administer-
ing HAART, a less severe form of HAD, comprising a milder cognitive
and motor disorder, is now potentially a serious problem (Gonzalez-
Scarano and Martin-Garcia, 2005).sion of CD4 and CXCR4 in U-87 cells. (A1) Puriﬁed total RNAwas reverse-transcribed and
CR4 expression in U-87 and MT-2 cells. (B) Infection of U-87 cells by HIV-2CBL23 isolate.
after infection. HIV-1NL4.3 infection (MOI 1) was the positive control of the experiment.
OI 1 or 2) in the presence or absence of anti-CXCR4 or AMD3100 during 16 h and then
t-Cycler RT-PCR kit. (D) COX-2 protein expression in HIV-2-U-87 and HIV-2-NHA cells
h of culture. Data are representative of at least 3 independent experiments. Differences
Fig. 3. Role of NFAT, AP-1, and NF-κB transcription factors in COX-2 transcriptional activity induced by HIV-2. (A) U-87 cells were transfected with the −73col-luc reporter plasmid
(AP-1-dependent), the NFAT-luciferase reporter plasmid, or with the κB-luciferase reporter plasmid and cultured in the presence of the isolate HIV-2CBL23 (MOI 1) during 16 h. (B) U-87
cells were cotransfected with the P2-1900 COX-2 promoter together with an expression vectors for the p65/relA, and IκBα subunits or an empty vector. U-87 cells were cultured in
presence or absence (control) of HIV-2CBL23 isolate (MOI 1) during 16 h and assayed for luciferase activity. Data shown are expressed as fold induction about basal values of untreated
cells. (C) NHA cells were treated with HIV-2CBL23 isolate alone or in combination with the NF-κB inhibitor PDTC (10 μM). PGE2 release was measured in the supernatants after 16 h of
culture. Differences fromHIV-2CBL23-induction of COX-2 promoter (P2-1900) in empty vector-transfected cells: ⁎p=0.01. Differences fromHIV-2CBL23-production of PGE2 in NHA cells:
⁎⁎pb0.01.
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several neurodegenerative diseases as well as in the cell damage
associated with neuroinﬂammation. Thus, elevated expression of
COX-2 mRNA and protein has been reported in Alzheimer's disease
(Pasinetti, 1998), and recently in AIDS infection (Alvarez et al., 2005;
Flora et al., 2006).
Since HIV-2CBL23 does not infect U-87 cells, the whole results
presented here show that COX-2 is induced in human astroglial cellsFig. 4. HIV-2 induces p65/relA transactivation but not IκBα degradation. (A) HIV-2 does not
2CBL23 (MOI 1) for the indicated time points (0–120 min). The cell lysates were blotted with
independent experiments. (B) HIV-2 induces activation p65/relA transactivation. Cells wer
(Ser529/536 to Ala) constructs and 100 ng of 5XGal4 luciferase reporter and cultured with
expressed as fold induction above control. (C) HIV-2CBL23 induces p65/relA phosphorylation
times. Whole cell lysates were prepared and blotted with p65/relA phospho-speciﬁc antiboby HIV-2 virus, being dependent on the presence of the viral core-
ceptor CXCR4. In addition, the transcriptional regulation of COX-2 by
HIV-2 involves NF-κB activation. Thus, we found that deletion of the
distal NF-κB element in the COX-2 promoter did reduce strongly
HIV-2-induced COX-2 promoter activity. Further deletion of a pro-
ximal NF-κB site completely abrogated this induction, indicating
that both NF-κB sites are responsible for COX-2 induction after HIV-
2 stimulation. The main role of NF-κB on COX-2 induction by HIV-2induce p65/relA translocation or IκBα degradation. U-87 cells were cultured with HIV-
antibodies speciﬁc for the p65/relA and IκBα. Western blot data are representative of 3
e cotransfected with 10 ng of the Gal4DBD-p65 wild type and Gal4DBD-p65 mutant
medium in basal condition or cultured with HIV-2CBL23 (MOI 1). Reporter activity is
in Ser536. U-87 cells were cultured with HIV-2CBL23 isolate (MOI 1) for the indicated
dy that detects phosphorylation at Ser536 position (indicated as P-p65 (Ser-536)).
Fig. 5. HIV-2 increases GFAP expression in U-87 cells. U-87 cells were cultured in the presence or absence of HIV-2CBL23 alone or in combination with the COX inhibitors, NS-398
(5 μM) and ibuprofen (10 μM). After 16 h, cells on coverslips were ﬁxed and stained with antibodies against the cell speciﬁc marker, GFAP. Original magniﬁcation ×40. Background
staining was observed using irrelevant antibodies.
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enough to induce COX-2 promoter activity and synergized with HIV-
2 in this induction. More importantly, cotransfection experiments
with a plasmid encoding for the NF-κB subunit inhibitory IκBα plus
the COX-2 promoter abrogated COX-2 transcriptional activity by
HIV-2. All our data indicate that NF-κB activation is required and
sufﬁcient for the upregulation of glial COX-2 expression by HIV-2.
Interestingly, HIV-2 induces NF-κB activation by a mechanism not
involving IκBα degradation or p65/relA translocation. Regulation of
the NF-κB pathway is also brought about through multiple post-
translational modiﬁcations that control the activity of the core
components of NF-κB signalling: the IKK complex, the IκB proteins
and the NF-κB subunits themselves. These regulatory modiﬁcations
can vary depending on the nature of the NF-κB-inducing stimulus.
Phosphorylation and degradation of IκB and the consequent
liberation of NF-κB do not seem to be sufﬁcient to activate NF-κB-
dependent transcription in some instances (Ghosh and Karin, 2002;
Viatour et al., 2005). NF-κB transactivation in the absence of
increased NF-κB nuclear translocation or induced IκBα degradation
was also reported in several cell types (Doerre and Corley, 1999;
Ghosh and Karin, 2002). Mutation of Ser529 and Ser536 eliminated
HIV-2-induced Gal-4 transactivation. This result ﬁts nicely with the
fact that HIV-2 induces Ser536 phosphorylation and suggests that
HIV-2 induces NF-κB activation through increases in the transacti-
vation potential of p65/rel due to phosphorylation in Ser536. The
inhibitory effect of IκBα overexpression on COX-2 induction by HIV-
2 may simply reﬂect that it sequesters nuclear p65/relA preventing
p65 phosphorylation. However, future work is needed to address
the exact mechanism by which HIV-2 achieves this effect on NF-κB
transactivation.
Reactive astrocytosis or gliosis, deﬁned mainly as an increase in
size and number of GFAP-positive cells, is a prominent feature of HIV-
1 infected persons (Sharer, 1992). We could demonstrate for the ﬁrst
time that HIV-2 modulates the state of astrocytic cells by upregulating
GFAP expression which is a marker for activated astrocytes in similar
way than HIV-1 does (Kohleisen et al., 1999). Interestingly, this effect
of HIV-2 could be blocked by COX-2 inhibitors. Along with these
results, previous data described that P2Y receptor-mediated reactive
astrogliosis occurs via induction of COX-2 derived PGE2 (Brambilla et
al., 1999).
In summary, we demonstrate here that HIV-2 efﬁciently induces
COX-2 transcription in human astrocytes through a novel pathway
depending on NF-κB response elements. To our knowledge this
represents the ﬁrst example of the existence of a new HIV-2 viral
mechanism of COX-2 induction in brain cells through regulation of NF-
κB p65/relA phosphorylation and transactivation. We also demon-
strate that, as a consequence of COX-2 induction, astrocytic activation
is increased, supporting an undescribed role of astrocytes in HIV-2-
associated neuropathogenesis. Further studies are required to effec-
tively evaluate the effects of COX-2 inhibitors in the pathogenesis of
the HIV-2 infection.Materials and methods
Cell culture and reagents
Normal human astrocytes (NHA) isolated from the cerebrum of 5-
month-old human fetuses were purchased from Cambrex (CC-2565,
NHA-Normal Human Astrocytes; Walkersville, MD, USA). NHA cells
were cultured by plating the cells at a density of 15,000 cells ⁄cm2 in
expansion media (AGM Bullet Kit media, Cambrex) according to the
manufacturer's protocol. The cells were incubated at 37 °C with 5%
humidiﬁed CO2 and allowed to reach about 95% conﬂuency. After this,
they were harvested using 0.25% trypsin and 1 mm EDTA for 5 min at
37 °C. The astrocytoma human cell line U-87, was routinely grown in
DMEM (Gibco) containing 10% heat-inactivated fetal calf serum, 1%
penicillin/streptomycin, and 2 mM L-glutamine (ICN Pharmaceuticals,
CostaMesa, CA,USA) at 37 °C in ahumidiﬁed atmosphere of 5%CO2.MT-
2 cells (T cell leukemia) were routinely grown in RPMI 1640 (Biochrom
KG Seromed), containing 10% heat-inactivated fetal calf serum, 1%
penicillin/streptomycin, and 2 mM L-glutamine (ICN Pharmaceuticals,
Costa Mesa, CA, USA) at 37 °C in a humidiﬁed atmosphere of 5% CO2.
The HIV-2CBL23 viral isolate (generously donated by Dr. Balbino
Alarcón, Centro de Biologia Molecular, Madrid, Spain), and a T
lymphocyte-adapted strain, HIV-1NL4.3 (X4) were used for infectivity
assays. Virus stocks were prepared by expanding viral isolates in PBL
and were titrated using the end point dilution method. The virus
stocks gave 104 to 105 TCID50 when PBL were inoculated on micro-
dilution plates and read 10 days after with Agp24 assay (INNOTEST
HIV antigen mAb, Innogenetics N.V., Zwijndrecht, Belgium) according
manufacturer's instructions. The sensitivity of the assay was 10 pg/ml.
To assess the purity of the virus stocks thawed aliquots were ﬁltered
through 0.22-μm ﬁlters before use.
AMD3100 was from NIH (AIDS Research and Reference Reagent
Program, Rockville, USA), and anti-CXCR4 monoclonal antibody was
purchased from R&D Systems (Europe, Abingdon, UK). Ibuprofen, and
LPS (lipopolysaccharide) were purchased from Sigma (St. Louis, MO).
The selective inhibitor of COX-2, NS-398, was from Cayman Chemical
Company (MI, USA). The agent PDTC was obtained from Santa Cruz
Biotechnology, Inc. Anti-human CD4-phycoeritrine (PE), and anti-
human CXCR4 antibodies were from Beckman Coulter (Marseille,
France).
HIV-2 infection of U-87 cells
U-87 cells were exposed to HIV-2CBL23 isolate, at different multi-
plicity of infection (MOI) for 2 h at 37 °C. At the end of this period, the
culture medium was removed, cells were extensively washed with
PBS, and complete medium was added to each well. Virus titers were
evaluated in the last washing buffer (time 0). Cell supernatants were
harvested 3 days post-infection to monitor p24 viral core antigen
production by ELISA. HIV-1NL4.3 infection was used as a positive con-
trol of the experiment.
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Human COX-2 promoter constructs were generated as previously
described (Iniguez et al., 2000). The pNF-κB-luc reporter plasmid con-
tains a trimer of the NF-κB-bindingmotif of the H-2k gene upstream of
the TK (thymidine kinase) minimal promoter and the luciferase
reporter gene. The pNFAT-luc reporter plasmid was a gift from Dr. G.
Crabtree (Department of Pathology, Howard Hughes Medical Institute,
Stanford University Medical School, Stanford, CA 94305, USA). It
contains three tandem copies of the distal NFAT site of the human IL-2
promoter fused to the minimal human IL-2 promoter. The p-73col-luc
reporter plasmid contains AP-1-binding region (-73/+63pb) of human
collagenase promoter. The p65/relA, and IκBα expression plasmids
were also generously provided by Dr. G. Crabtree. The reporter Gal-
4Luc contains ﬁve tandem repeats of the Gal4 element upstream the
luciferase reporter gene (Martin and Fresno, 2000). Thewild typeGal4-
p65 ΔN plasmid active in binding to Gal4-binding sites as well as in
transactivation, containing amino acids 386-551 of p65/relA and the
Gal4 Ser529 and Ser536 to Ala mutant were a generous gift of Dr. L.
Schmitz (Schmitz and Baeuerle, 1991).
CD4 and CXCR4 detection
The expression of CD4 and CXCR4 was evaluated by reverse trans-
criptase-polymerase chain reaction (RT-PCR). The mRNA from 105
cells was isolated using SV Total RNA Isolation System (Promega
Corporation, Madison), according to the manufacturer's instructions
and cDNA synthesis with AccessQuick RT-PCR System (Promega
Corporation, Madison). The polymerase chain reaction was carried
out in an automatic Thermal Cycler (Perkin-Elmer GeneAmp PCR
system 9600). Ampliﬁed cDNAswere separated by agarose gel electro-
phoresis and bands visualized by ethidium bromide staining.
Flow cytometry
The expression of CD4 and CXCR4 cell surface antigens was
determined by ﬂow cytometry by using a FAC Sort (Epics XL-MCL
Beckman Coulter).
COX-2 mRNA quantiﬁcation by real-time PCR
Real-time PCR using 200 ng of total RNA was performed using a
Roche Light-Cycler PCR instrument and Light-Cycler RT-PCR kit (Roche
Perkin-Elmer, Foster City, California, USA). The standard used to make
the control curve was the commercial plasmid pCRTM II (Invitrogen
Corporation, Life Technologies, Rockville, MD, USA) where a fragment
of the COX-2 promoter was inserted. The number of molecules of the
plasmid was quantiﬁed measuring the quantity of DNA in a spectrum-
photometer. As the weight of the standard (plasmid+sequence of
COX-2) was known the exact number ofmolecules can be extrapolated.
PGE2 determination
Supernatants of U-87 andNHA cells after different treatmentswere
tested for PGE2 production using a competitive enzyme immunoassay
using the PGE2 EIA kit (Cayman Chemical Company, MI, USA).
Transfection and luciferase assays
Transcriptional activity was measured using luciferase reporter
gene assays in transiently transfectedU-87 cells. Cellswere transfected
by Lipofectin reagent as recommended by the manufacturer (Life
Technologies, Rockville, MD, USA). Brieﬂy, exponential growing cells
(1.5×106) were incubated for 8 h at 37 °Cwith amixture of 1.5 μg/ml of
the corresponding reporter plasmid and 3 μg/ml lipofectin in 1 ml of
Opti-MEM Reduced Serum Medium modiﬁcation of MEM (Eagle's)(GIBCO-BRL, Invitrogen Corporation). In cotransfection experiments,
0.15–0.5 μg/ml of the correspondent expression plasmid was included.
The total amount of DNA in each transfection was kept constant by
using the corresponding empty expression vectors. Cells were then
resuspended in completemediumand incubated at 37 °C for additional
16 h. Transfected cells were exposed to different stimuli as indicated.
Then, cells were harvested and lysed. Luciferase activity was deter-
mined by using a luciferase assay kit (Promega Corporation, Madison,
USA) with a luminometer 1450 Microbeta Luminiscence Counter
(Walax, Trilux). Protein contents were measured using the bicincho-
ninic acid method (BCA protein assay kit from Pierce, Rockford, USA)
according to the manufacturer's instructions. The data presented are
expressed as fold induction respect untreated cells of at least 3 inde-
pendent experiments.
Western blot analysis
Human primary astrocytes and U-87 cells were exposed to HIV-
2CBL23 isolate for different times. Protein contents were measured
using BCA protein assay according to the manufacturer's instructions.
ForWestern blotting, 20 μg of protein from each sample was subjected
to SDS-polyacrylamide gel electrophoresis (PAGE) on a 7.5% gel.
Proteins were then transferred onto a PVDF ﬂuoride membrane
(Millipore, Bedford, MA, USA) by humidiﬁed transference blotting.
The membrane was blocked overnight at 4 °C using Rotiblock (Roth,
Karlsruhe) and for another hour at room temperature before incuba-
tionwith the primaryantibodies: amouse anti-humanCOX-2 (Cayman
Chemical Company, MI, USA), a mouse anti-human p65/relA NF-κB
(Chemicon International, USA), a mouse anti-IκBα subunit, a rabbit
anti-Ser 536 phosphorylated p65/relA (Santa Cruz Biotechnology, Inc)
or a mouse anti-humanα-tubulin (Sigma, St. Louis, MO). Visualization
of protein bands was performed using enhanced chemiluminescence
(ECL) reagents (Amersham Biosciences, UK). All Western blot experi-
ments were carried out at least three times. In some cases as loading
control, blots were probed for tubulin using a speciﬁc antibody.
Indirect immunoﬂuorescence assays
U-87 cells were pretreated or not with different COX-2 inhibitors
for 2 h beforeHIV-2CBL23 culture during 16 h, and left to adhere to slides
during 2 h at 37 °C. Monolayers were ﬁxed for 20 min in 4% para-
formaldehyde. Cultures were incubated for 1 h with primary
monoclonal antibody anti-human GFAP 1:100 (Chemicon Interna-
tional, MI, USA). Following washing with PBS, the monolayers were
incubated in the dark for half an hour with goat anti-human ﬂuo-
rescein isothiocyanate (FITC) conjugated (Jackson ImmunoResearch,
Baltimore, USA). Following a ﬁnal PBS wash, the slides were mounted
with DAKO® Ultramount, Aqueous Permanent Mounting Medium
(DAKO Corporation, CA, USA).
Statistical analysis
The data were expressed as the mean±S.E. from three to six inde-
pendent experiments. Differences were analyzed using non-para-
metric tests (Mann–Whitney “U”).
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